No Results Found
Try adjusting your search to find what you’re looking for.
5/23/2023
Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital
Led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change. Illumina Ventures’ Charles Lin, PhD, who has joined Pluton’s Board of Directors, expressed his excitement about the fund’s first AgBio investment, “In the past two decades, we have witnessed how genomics revolutionized the landscape of human diagnostics and therapeutics. We expect genomics to...
Read More
5/03/2023
Company Spotlight – Sherlock Biosciences
Diagnostic tests are vital, but the current system can be challenging. Blood draw sites are often inconvenient, and patients can wait days for results. In addition, people testing for sexually transmitted diseases (STDs), and other potentially sensitive conditions, may opt-out over privacy concerns.
Sherlock Biosciences is working to address these issues by changing how people access diagnostics.
Read More
4/25/2023
Walking Fish Therapeutics Is Focused On Regeneration
Walking Fish Therapeutics was named after the Axolotl, a small amphibian that can regenerate lost limbs and even a damaged heart. The company’s co-founder, chairman and CEO, Rusty Williams, MD, PhD, has long marveled at this capacity and draws on it for inspiration.
Read More
4/13/2023
Alamar Biosciences Prepping Proteomics Platform for 2024 Launch
Proteomics firm Alamar Biosciences is preparing its NULISA (NUcleic acid-Linked Immuno-Sandwich Assay) platform for an early-access release later this year and a broad commercial launch in 2024. The NULISA system is based on the proximity ligation assay (PLA) originally commercialized by Olink Bioscience, the forerunner of Olink. PLA uses pairs of antibodies attached to unique DNA sequences to...
Read More